TRIPLE-NEGATIVE BREAST CARCINOMA

This study tested whether adding the drug trastuzumab to standard chemotherapy before surgery helps shrink breast tumors more effectively. It involved 92 women with early-stage breast cancer who had not received prior treatment. The main goals were to see if the combination was s…

This large, late-stage trial is testing whether a one-year course of the immunotherapy drug pembrolizumab can help prevent cancer from returning in patients with high-risk triple-negative breast cancer. The study involves over 1,100 patients whose cancer showed significant remain…

This is an early-stage safety study testing a new drug called BAY 1895344 when given with standard chemotherapy drugs (cisplatin with or without gemcitabine). The main goals are to find the safest dose and understand the side effects in people with advanced solid tumors that have…

This early-stage trial is testing a new combination of two drugs, veliparib and carboplatin, for people with advanced HER2-negative breast cancer that has spread. The main goals are to find the safest and most effective dose and to understand the side effects. Researchers hope th…

This early-stage study is testing the safety and best dose of a new two-drug combination (ZEN003694 and binimetinib) for people with advanced solid tumors that have specific genetic changes. The main goal is to see what side effects occur and find a dose that is safe for future t…

This early-phase study is testing the safety of combining a new cancer vaccine with an existing immunotherapy drug (pembrolizumab) in patients with advanced solid tumors that have spread and stopped responding to standard treatments. The vaccine is designed to train the immune sy…

This study is testing if adding a targeted drug called panitumumab to standard chemotherapy works better than chemotherapy alone before surgery for a fast-growing, hard-to-treat type of breast cancer. It aims to see which combination shrinks the tumor more effectively, potentiall…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This early-stage trial is testing whether adding an experimental drug called berzosertib to standard radiation therapy can better control breast cancer that has not responded well to chemotherapy. The main goal is to find the safest and most effective dose of the drug when given …

This study is for patients with a specific, aggressive type of breast cancer (triple-negative, basal-like) where cancer cells remain after initial chemotherapy and surgery. It aims to find out which of two follow-up chemotherapy drugs—platinum-based drugs (cisplatin/carboplatin) …

This study is testing whether taking two oral drugs, cediranib and olaparib, together can help control advanced cancers that have spread or cannot be surgically removed. It is for adults with specific types of advanced lung, breast, or pancreatic cancer who have already tried at …

This study is testing if adding an immunotherapy drug (atezolizumab) to standard chemotherapy before surgery works better for treating early-stage triple-negative breast cancer. It will compare two groups: one gets chemo alone, and the other gets chemo plus the immunotherapy drug…

This study tested whether the immunotherapy drug pembrolizumab could help control advanced inflammatory or triple-negative breast cancer in patients whose disease had already responded to or stabilized with chemotherapy. The trial involved 71 participants with these aggressive fo…

This study is testing an experimental vaccine called STEMVAC in people with early-stage triple-negative breast cancer who have already finished their standard treatments. The goal is to see if the vaccine can safely 'wake up' the immune system to recognize and attack specific pro…

This early-stage trial is testing the safety and best doses of two different combinations of oral medications for people with recurrent endometrial, ovarian, or triple-negative breast cancer. The study combines an existing drug (olaparib) with one of two newer drugs (AZD2014 or A…

This study tested a combination of two drugs, cediranib and olaparib, for people with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer. The goal was to see if using both drugs together is safe and works better than using olaparib alone to control th…

This study is testing whether two advanced imaging scans can predict how well chemotherapy will work for patients with triple-negative breast cancer before they have surgery. Researchers will compare these new scans to standard imaging to see which method better identifies patien…

This study aimed to test an online mental health program designed to help women with advanced breast or gynecologic cancers manage their fear of the cancer returning or getting worse. It planned to compare this virtual program to standard educational resources. The goal was to se…

This study aims to find the best way to help women understand their genetic cancer risk with less stress. It compares watching an online educational video alone to combining it with phone counseling sessions. The goal is to see which method helps participants feel less distressed…

This study is testing a blood test that looks for tiny pieces of leftover cancer DNA after treatment for early-stage breast cancer. The goal is to see if this test can identify patients who still have hidden cancer cells and might benefit from additional therapy. Researchers will…